All News
Filter News
Found 310 articles
-
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
6/2/2022
Featured speakers include Dr. John Krystal, Yale School of Medicine, and Dr. David Nutt, Imperial College London.
-
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT THE 36TH ANNUAL SLEEP 2022 MEETING
6/2/2022
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO® CIV) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022).
-
Mirati Therapeutics' adagrasib is going up against Amgen’s Lumakras in the KRAS race, and according to Friday pre-market trading, the results shared Thursday don't seem to be enough for investors.
-
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
5/26/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
5/19/2022
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
-
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
5/19/2022
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec (B-VEC), an investigational, topical gene therapy for dystrophic epidermolysis bullosa (DEB)” at the Society for Investigative Dermatology 2022 Annual Meeting.
-
Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
5/9/2022
Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced the completion of its U.S. acquisition of Sunosi® from Jazz Pharmaceuticals.
-
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
5/9/2022
Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today reported financial results and key operational progress updates for the first quarter ending March 31, 2022.
-
Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
5/4/2022
Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, reported financial results for the first quarter of 2022 and recent corporate updates.
-
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
5/3/2022
Krystal Biotech, Inc. announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in the Bank of America Merrill Lynch Global Healthcare Conference.
-
Global KRAS Inhibitors Drug Market Clinical Trials Forecast 2028
4/29/2022
"Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights.
-
Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
4/27/2022
Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research showcasing the potential of its investigational KRASG12C inhibitor, adagrasib, in a study of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
4/11/2022
Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, the opportunity to be dosed in their homes by a health care professional (HCP).
-
The U.S. Food and Drug Administration (FDA) has approved BioXcel Therapeutics' Igalmi, a drug designed to reduce agitation episodes in bipolar disorder and schizophrenia patients.
-
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults
4/6/2022
BioXcel Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
-
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
3/28/2022
Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that results from the Phase 1 and 2 study of topical beremagene geperpavec (B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) were published in Nature Medicine.
-
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
3/26/2022
Krystal Biotech, Inc., the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec, an investigational, topical gene therapy, for the treatment of dystrophic epidermolysis bullosa, at the 2022 American Academy of Dermatology Annual Meeting in Boston, Mass.
-
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
3/24/2022
Krystal Biotech, Inc. announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3rd Annual Genomic Medicines and Rare Disease Day.